EN | TR
E-ISSN: 3061-9947
Factors affecting the development of recurrence in stage I low grade - endometrial stromal sarcoma; multicentre retrospective study
PDF
Cite
Share
Request
Original Article
VOLUME: 51 ISSUE: 3
P: 409-415
2018

Factors affecting the development of recurrence in stage I low grade - endometrial stromal sarcoma; multicentre retrospective study

Acta Haematol Oncol Turc 2018;51(3):409-415
DOI: 10.5505/aot.2018.94840
Varol Gülseren 1
Mustafa Kocaer 2
Anıl Turhan Çakır 3
Müge Harma 3
Mehmet İbrahim Harma 3
İsa Aykut Özdemir 4
Muzaffer Sancı 2
Kemal Güngördük 5
1. Kaman State Hospital, Department of Obstetrics and Gynecology, Kırşehir, Turkey
2. Tepecik Education and Research Hospital,Department of Obstetrics and Gynecology, Izmir,Turkey
3. University of Bülent Ecevit, Department of Obstetrics and Gynecology, Zonguldak, Turkey
4. Bakirkoy Sadi Konuk Research and Training Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey
5. University of Muğla Sıtkı Koçman, Department of Obstetrics and Gynecology, Mugla, Turkey
6.
No information available.
No information available
Received Date: 2018-04-14T14:47:57
Accepted Date: 2018-12-28T10:55:14
PDF
Cite
Share
Request

Abstract

INTRODUCTION

To investigate patients with stage I, low-grade endometrial stromal sarcoma (LG-ESS) which is rare and has good prognosis and to evaluate prognostic factors affecting recurrence.

METHODS

Twenty-four patients with stage I LG-ESS diagnosis and followed-up in Tepecik Education and Research hospital and medical faculty of Zonguldak Bülent Ecevit University were investigated as retrospective. Patients who had undergone surgery and had follow-up at these two centers between 1998 and 2016 were included in the study. Exclusion criteria were endometrial stromal nodule or undifferentiated stromal sarcoma histologic types, stage II, III and IV ESS, accompanying malignancies and non-follow-up patients.

RESULTS

The effects of age, adjuvant radiotherapy (RT), myometrial invasion (MI), tumor size and number of mitotic figures on the recurrence risk of patients with stage I LG-ESS in follow-up were analyzed according to logistic regression analysis and it was found that there was a significant correlation between the risk of recurrence and presence of ≥5 mitosis in 10 microscopic high power fields. The effects of prognostic factors on disease free (DFS) and overall survival (OS) outcomes were investigated, but there was no statistically significant factor. 5-year OS and 10-year OS for Stage I, LG-ESS patients were calculated as 100% and 86.2%, respectively; 5-year DFS and 10-year DFS for those patients were 91.7% and 85.1%, respectively.

DISCUSSION AND CONCLUSION

LG-ESS patients have excellent prognosis and adjuvant RT therapy has no effect on prognosis. These patients have long survival time, adjuvant RT treatment should be considered in recurrence treatment.